These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38735381)

  • 1. Targeting STAT3 potentiates CDK4/6 inhibitors therapy in head and neck squamous cell carcinoma.
    Dong L; Liu C; Sun H; Wang M; Sun M; Zheng J; Yu X; Shi R; Wang B; Zhou Q; Chen Z; Xing B; Wang Y; Yao X; Mei M; Ren Y; Zhou X
    Cancer Lett; 2024 Jul; 593():216956. PubMed ID: 38735381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma.
    Ku BM; Yi SY; Koh J; Bae YH; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Oncotarget; 2016 Mar; 7(12):14803-13. PubMed ID: 26909611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Kinome-Wide Synthetic Lethal CRISPR/Cas9 Screen Reveals That mTOR Inhibition Prevents Adaptive Resistance to CDK4/CDK6 Blockade in HNSCC.
    Goto Y; Koshizuka K; Ando T; Izumi H; Wu X; Sato K; Ishikawa T; Ford K; Feng X; Wang Z; Arang N; Allevato MM; Kishore A; Mali P; Gutkind JS
    Cancer Res Commun; 2024 Jul; 4(7):1850-1862. PubMed ID: 38954773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma.
    Yun MR; Choi HM; Kang HN; Lee Y; Joo HS; Kim DH; Kim HR; Hong MH; Yoon SO; Cho BC
    Oncogene; 2018 Jan; 37(3):377-388. PubMed ID: 28945228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest.
    Wang J; Li Q; Yuan J; Wang J; Chen Z; Liu Z; Li Z; Lai Y; Gao J; Shen L
    J Transl Med; 2017 Jun; 15(1):127. PubMed ID: 28578693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.
    Mohan S; Vander Broek R; Shah S; Eytan DF; Pierce ML; Carlson SG; Coupar JF; Zhang J; Cheng H; Chen Z; Van Waes C
    Clin Cancer Res; 2015 Sep; 21(17):3946-56. PubMed ID: 25977343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. JAK kinase inhibition abrogates STAT3 activation and head and neck squamous cell carcinoma tumor growth.
    Sen M; Pollock NI; Black J; DeGrave KA; Wheeler S; Freilino ML; Joyce S; Lui VW; Zeng Y; Chiosea SI; Grandis JR
    Neoplasia; 2015 Mar; 17(3):256-64. PubMed ID: 25810010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual induction of apoptotic and autophagic cell death by targeting survivin in head neck squamous cell carcinoma.
    Zhang L; Zhang W; Wang YF; Liu B; Zhang WF; Zhao YF; Kulkarni AB; Sun ZJ
    Cell Death Dis; 2015 May; 6(5):e1771. PubMed ID: 26018732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical Activity of Ribociclib in Squamous Cell Carcinoma of the Head and Neck.
    van Caloen G; Schmitz S; El Baroudi M; Caignet X; Pyr Dit Ruys S; Roger PP; Vertommen D; Machiels JP
    Mol Cancer Ther; 2020 Mar; 19(3):777-789. PubMed ID: 31924739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. STAT3 blockade enhances the efficacy of conventional chemotherapeutic agents by eradicating head neck stemloid cancer cell.
    Bu LL; Zhao ZL; Liu JF; Ma SR; Huang CF; Liu B; Zhang WF; Sun ZJ
    Oncotarget; 2015 Dec; 6(39):41944-58. PubMed ID: 26556875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SPH3643: A novel cyclin-dependent kinase 4/6 inhibitor with good anticancer efficacy and strong blood-brain barrier permeability.
    Liao X; Hong Y; Mao Y; Chen N; Wang Q; Wang Z; Zhang L; Wang L; Shi C; Shi W; Ge H; Li A; Li X; Xia G; Liu Y
    Cancer Sci; 2020 May; 111(5):1761-1773. PubMed ID: 32103527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated RET expression enhances EGFR activation and mediates EGFR inhibitor resistance in head and neck squamous cell carcinoma.
    Lin C; Lu W; Ren Z; Tang Y; Zhang C; Yang R; Chen Y; Cao W; Wang L; Wang X; Ji T
    Cancer Lett; 2016 Jul; 377(1):1-10. PubMed ID: 27090738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p53-targeted lincRNA-p21 acts as a tumor suppressor by inhibiting JAK2/STAT3 signaling pathways in head and neck squamous cell carcinoma.
    Jin S; Yang X; Li J; Yang W; Ma H; Zhang Z
    Mol Cancer; 2019 Mar; 18(1):38. PubMed ID: 30857539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miR-204 inhibits angiogenesis and promotes sensitivity to cetuximab in head and neck squamous cell carcinoma cells by blocking JAK2-STAT3 signaling.
    Wu Q; Zhao Y; Wang P
    Biomed Pharmacother; 2018 Mar; 99():278-285. PubMed ID: 29353201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Stat3 abrogates EGFR inhibitor resistance in cancer.
    Sen M; Joyce S; Panahandeh M; Li C; Thomas SM; Maxwell J; Wang L; Gooding WE; Johnson DE; Grandis JR
    Clin Cancer Res; 2012 Sep; 18(18):4986-96. PubMed ID: 22825581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Honokiol inhibits epidermal growth factor receptor signaling and enhances the antitumor effects of epidermal growth factor receptor inhibitors.
    Leeman-Neill RJ; Cai Q; Joyce SC; Thomas SM; Bhola NE; Neill DB; Arbiser JL; Grandis JR
    Clin Cancer Res; 2010 May; 16(9):2571-9. PubMed ID: 20388852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Galangin inhibits growth of human head and neck squamous carcinoma cells in vitro and in vivo.
    Zhu L; Luo Q; Bi J; Ding J; Ge S; Chen F
    Chem Biol Interact; 2014 Dec; 224():149-56. PubMed ID: 25450235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dihydroartemisinin as a Putative STAT3 Inhibitor, Suppresses the Growth of Head and Neck Squamous Cell Carcinoma by Targeting Jak2/STAT3 Signaling.
    Jia L; Song Q; Zhou C; Li X; Pi L; Ma X; Li H; Lu X; Shen Y
    PLoS One; 2016; 11(1):e0147157. PubMed ID: 26784960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SKLB188 inhibits the growth of head and neck squamous cell carcinoma by suppressing EGFR signalling.
    Barzegar M; Ma S; Zhang C; Chen X; Gu Y; Shang C; Jiang X; Yang J; Nathan CA; Yang S; Huang S
    Br J Cancer; 2017 Oct; 117(8):1154-1163. PubMed ID: 28873083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. S-Nitrosoglutathione-mediated STAT3 regulation in efficacy of radiotherapy and cisplatin therapy in head and neck squamous cell carcinoma.
    Kaliyaperumal K; Sharma AK; McDonald DG; Dhindsa JS; Yount C; Singh AK; Won JS; Singh I
    Redox Biol; 2015 Dec; 6():41-50. PubMed ID: 26177470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.